Peptide Impurities Explained: Deletion Sequences, Oxidation and Related Substances

Published October 2026 · Patriot Labs Research Team · ~22 min read

The short answer

Peptide impurities are everything in a vial that is not the intended target peptide. They divide into peptide-related substances — molecules closely related to the target, such as deletion and truncation sequences, insertion sequences, epimers, and oxidation, deamidation and dimer products — and non-peptide impurities, such as counterions, residual solvents, water and inorganic residues. A purity figure like 98 percent describes how much of the peptide material is the target sequence; the rest is this related material.

Those impurities arise in two phases. Some are made during synthesis, when the chain is assembled one residue at a time and the chemistry is never perfect: a coupling that stalls leaves a shorter chain, a protecting group that lingers leaves an adduct, an aspartate that cyclises leaves a ring-opened mixture. Others appear afterward, during purification, drying and storage, when sensitive residues oxidise, amide side chains hydrolyse, and molecules pair up. Purification removes most of this, but it cannot remove by-products whose size and shape are almost identical to the target, which is why no synthetic peptide reaches absolute purity.

The rest of this guide takes the main classes in turn, explains the chemistry that produces each one, and then covers how analysts separate, weigh and report them, and what the regulatory thresholds for a peptide-related impurity are. For the manufacturing context behind these reactions, see How Peptides Are Made and What Is Solid-Phase Peptide Synthesis; for how the resulting numbers are read, see Understanding Peptide COA Testing.

The two families of impurity

Impurities in a synthetic peptide fall into two families: peptide-related substances, which are themselves peptides closely related to the target, and non-peptide impurities, which are the chemical residues left by the process. The distinction matters because the two families are measured by different tests and appear in different parts of a certificate of analysis.

A 2014 review of related impurities in peptide medicines sorts the peptide-related family by where it comes from: impurities generated during solid-phase synthesis — deletions and insertions, incomplete deprotection, side-chain adducts, oxidation, diastereomers, dimers and counterions — and impurities generated by intrinsic degradation, such as beta-elimination, diketopiperazine, pyroglutamate and aspartimide (succinimide) formation.^[1] A third group, formed by reaction between the peptide and the excipients of a finished formulation, exists only in formulated drug products and is outside the scope of a lyophilised research powder.^[1] The same review notes that individual-impurity control should focus first on synthesis by-products such as diastereomeric and deamidated peptides.^[1]

The regulatory language is slightly different but maps onto the same idea. The FDA’s 2021 guidance on certain highly purified synthetic peptides defines a peptide-related impurity as a molecule with an amino acid sequence “related to, but different from” the active ingredient, arising from “insertion, deletion, or other modifications (e.g., oxidation or glycosylation) to the amino acid sequence,” together with residues of the peptide.^[2] Non-peptide impurities — residual solvents, elemental impurities and the like — are handled by separate general standards rather than by the peptide-specific rules.^[2][15][16]

Deletion and truncation sequences

Deletion and truncation sequences are chains that are missing one or more residues of the intended sequence, and they are the most common peptide-related impurity. They form because solid-phase synthesis builds the chain one residue at a time, and no coupling step reaches 100 percent completion.

In solid-phase peptide synthesis the chain is assembled from its C-terminal end toward the N-terminal end, each cycle removing a temporary protecting group and coupling the next activated amino acid.^[1][4] If a coupling does not go all the way to completion, a fraction of the chains on the resin never receive that residue. When the next cycle proceeds, those chains simply continue growing without it, and the end product includes a population that is internally short by one amino acid — a deletion sequence. The 2014 review ties deletions specifically to inefficient deprotection and incomplete coupling during synthesis.^[1] A related case is the truncation sequence, a chain that stopped growing early; capping steps are used precisely so that stalled chains are terminated and show up as a clean shorter product rather than a near-full-length deletion.

The signature of a deletion is a mass lower than the target by exactly the mass of the missing residue — for example a glycine deletion is lighter by 57 daltons, an alanine deletion by 71 — which makes mass spectrometry the natural tool for pinning down which residue is absent. Many deletions are also chemically different enough from the target to separate on reversed-phase HPLC as their own peak, which is how they are counted. The longer the sequence, the more coupling steps there are, and the more the small per-step losses compound; this is one reason long peptides are harder to make to high purity than short ones, a point developed in How Peptides Are Made.

Insertion sequences and incomplete deprotection

Insertion sequences carry an extra residue, and protecting-group impurities carry chemical caps that should have come off; both are synthesis by-products that make the chain heavier rather than lighter. They are less common than deletions but are tracked for the same reason — each shifts the mass by a defined amount.

An insertion arises when a single residue is coupled twice, so the chain gains an extra copy of that amino acid; the 2014 review attributes insertions to the excess of activated amino acid used to drive couplings to completion.^[1] The result is a chain heavier than the target by one residue’s mass, the mirror image of a deletion. Pre-activation and controlled reagent stoichiometry reduce them.

Incomplete deprotection leaves part of the protecting-group scaffold attached to the finished peptide. Side chains are masked during synthesis by groups such as tert-butyl, trityl and Pbf, and the N-terminus by a temporary Fmoc group; the final acid cleavage is meant to strip the side-chain groups while releasing the peptide from the resin.^[1] When a group is not fully removed, or when a reactive fragment released during cleavage re-attaches to a vulnerable side chain, the product carries an adduct heavier than the target by that group’s mass. Incomplete Fmoc removal during the build contributes to low yields and to the deletion population, and is mitigated by extending or repeating the deprotection step and, in difficult cases, adding a stronger base such as DBU; morpholine has also been examined as a gentler alternative to piperidine for the removal step.^[8][10] A well-documented example of re-addition is the migration of the Pmc or Pbf group from a protected arginine onto the indole ring of an unprotected tryptophan during acid cleavage, the extent of which depends on how close the two residues sit in the sequence; using a protected tryptophan building block prevents it.^[8][12] The chemistry of these masking groups is covered in What Is a Protecting Group and Fmoc vs Boc Peptide Synthesis.

Aspartimide: the signature side reaction

Aspartimide formation is the best-studied and most troublesome synthesis side reaction, because a single aspartate residue can generate a whole family of by-products, several of which are almost impossible to separate from the target. It is both a synthesis and a degradation reaction, catalysed by the bases used in synthesis and by acid.

The mechanism begins when the nitrogen of the peptide backbone attacks the protected carboxyl side chain of an aspartate residue, closing a strained five-membered ring called an aspartimide (a succinimide).^[5][8] That ring is chemically unstable and chirally labile: it opens again by addition of water or of the base used in Fmoc removal, and it racemises as it does so. The result is not one impurity but a set — the normal (alpha-linked) peptide and a rearranged beta-linked peptide, each in its natural L form and its mirror-image D form, plus adducts in which piperidine has added to the ring.^[5][6][8] A classic manufacturer study reports that this single reaction can ultimately generate nine different by-products.^[6]

The reaction is strongly sequence-dependent. It occurs predominantly when aspartate is followed by glycine, asparagine, aspartate, glutamine or arginine, with aspartate-glycine described as the worst case.^[6][8] In a widely used model peptide, standard aspartate side-chain protection produced aspartimide at measurable rates per deprotection cycle and left a substantial fraction as the D-epimer, while bulkier side-chain esters cut both the aspartimide rate and the D-content by roughly an order of magnitude.^[5][6] That is why modern protocols for aspartate-rich sequences reach for specialised side-chain protecting groups, backbone amide protection, or additives, and keep base-exposure times short.^[6][8]

What makes aspartimide the cautionary tale of peptide purity is detectability. The manufacturer study notes that the aspartimide itself and its piperidide adducts can usually be separated from the target by HPLC, but the beta-aspartyl peptide and the D-epimer frequently share the target’s retention time and its exact mass, so neither chromatography nor mass spectrometry alone reliably reveals them.^[6] An impurity that is isobaric with the target and co-elutes with it is the hardest kind to catch, and it is the reason aspartate-containing sequences get particular scrutiny in method development.

Epimers and D-amino acids

An epimer is a peptide in which one residue has flipped from the natural L configuration to the mirror-image D configuration. Epimers are a demanding impurity class because a single flipped centre leaves the molecular formula and mass unchanged, so mass spectrometry cannot distinguish them from the target.

Racemisation happens mainly at the moment an amino acid is activated for coupling: activation makes the alpha-carbon acidic enough that it can lose and regain its proton, and a fraction of molecules regain it on the wrong face.^[1] Some residues are more prone than others, and some activation chemistries are harsher than others, which is why coupling conditions are chosen partly to keep epimerisation low. Aspartimide formation is a second route to D-residues, because the ring-opening step racemises the aspartate as described above.^[5][8] Because epimers are isobaric with the target, they are detected by their slightly different behaviour on reversed-phase HPLC, and in demanding cases by chiral analysis that measures the D/L ratio of each residue directly; the 2014 review places diastereomeric peptides among the synthesis impurities that control strategies should prioritise.^[1] The broader chemistry of L and D residues, and why the body’s machinery is built around one hand, is the subject of D-Amino Acids in Peptides.

Oxidation, deamidation and rearrangement

Oxidation and deamidation are the two most important degradation impurities — the ones that grow during purification, drying and storage rather than during assembly. Both act on specific residues, and both shift the mass by a small, predictable amount that makes them straightforward to identify once they are separated.

Oxidation. Several residues are vulnerable to oxidation by dissolved oxygen, trace metals and light. Methionine is the classic case: its sulfur is readily oxidised to a sulfoxide, adding a single oxygen atom and therefore about 16 daltons, and the reaction is described as frequently observed in peptide work.^[8] Cysteine, tryptophan and histidine can oxidise as well. Methionine sulfoxide is reversible — it can be reduced back with reagents such as ammonium iodide and dimethyl sulfide, or with thiol reductants in workup — and because the sulfoxide is more polar it even shifts the peptide’s HPLC retention in a recognisable way.^[8][11] Oxidation is the main reason reconstituted peptides are protected from air and light, a handling point developed in How Peptides Degrade.

Deamidation. Asparagine and glutamine carry an amide side chain that can hydrolyse, converting the amide to a carboxylic acid. The reaction most often proceeds through a cyclic succinimide intermediate — the same ring chemistry as aspartimide — which then opens to a mixture of the normal aspartate and a rearranged iso-aspartate, usually favouring the iso form.^[1] Deamidation replaces an –NH₂ with an –OH, a net mass increase of about one dalton, and it tends to produce a slightly later-eluting peak; it is fastest when asparagine is followed by glycine, and it accelerates with pH and temperature. The 2014 review lists deamidated peptides, alongside diastereomers, as a priority target for impurity control.^[1]

Backbone and side-chain rearrangements. Serine- and threonine-containing sequences can undergo an N-to-O acyl shift during acid treatment, in which the chain migrates from the backbone nitrogen onto the residue’s hydroxyl group through a cyclic intermediate; the shift is reversible with mild base.^[8] These rearrangements usually leave the mass unchanged, so, like epimers, they are seen chromatographically rather than by mass alone.

Diketopiperazine, pyroglutamate and end-group chemistry

A further group of impurities forms at the ends of the chain, where free amino and carboxyl groups can cyclise onto their neighbours. These end-group reactions are collected together because they share a mechanism — an internal nucleophile closing a small ring — and because they are listed among the intrinsic degradation pathways of peptides.^[1]

Diketopiperazine (DKP). Once the first two residues of a chain are in place and the N-terminal protecting group is removed, the freed amine can attack the amide bond two residues away and close a six-membered diketopiperazine ring, releasing a dipeptide. The reaction is favoured by the basic conditions of Fmoc removal and is especially facile when the second residue is a proline, whose secondary amine is a strong nucleophile.^[8] On resins where the chain is anchored through an ester, DKP formation can cleave the growing peptide off the support entirely.^[8] Work on optimising the Fmoc-removal step has focused specifically on suppressing both conventional and “traceless” DKP formation.^[9]

Pyroglutamate. An N-terminal glutamine (or glutamate) can cyclise onto the backbone to form a pyroglutamate ring, blocking the N-terminus and dropping ammonia or water. It is counted among the standard peptide degradation routes.^[1]

Beta-elimination and related losses. The 2014 review also lists beta-elimination among intrinsic degradation mechanisms; a C-terminal cysteine, for instance, can lose its thiol protecting group and eliminate to a dehydroalanine, to which piperidine then adds — a route that produces a defined piperidinyl-alanine by-product.^[1][8]

Dimers, aggregates and disulfide scrambling

Not every impurity is smaller than or the same size as the target; some are larger, because peptide molecules can join to each other. Dimers, higher oligomers and aggregates are tracked as a distinct class, and they are the reason a related-substances test should look at higher-molecular-weight species as well as lower ones.

The 2014 review lists dimeric-to-oligomeric species among synthesis-related impurities.^[1] The commonest chemical route is through cysteine: a peptide meant to hold one internal disulfide bond can instead pair its thiol with a second molecule, giving a covalent dimer, or form the bond between the wrong pair of cysteines, giving a scrambled isomer with the correct mass but the wrong connectivity. Peptides can also aggregate non-covalently, and for some sequences this is what turns a reconstituted solution cloudy or gelatinous — a physical-stability problem distinct from chemical purity. A covalent dimer carries roughly twice the target’s mass and elutes early on a size-exclusion column, so it is comparatively easy to see; a disulfide-scrambled monomer shares the target’s mass and, like an epimer, has to be resolved chromatographically or by mapping the disulfide bonds. The role of disulfide bonds in holding a peptide’s shape is covered in What Is a Disulfide Bond.

Non-peptide impurities: counterions, solvents, water and metals

The second family of impurities is not peptide at all. It is the chemical residue the process leaves behind — the counterion paired with the peptide’s charges, leftover solvents, bound water and traces of metals — and it is measured by its own tests rather than by the purity peak.

Counterions. A synthetic peptide is a salt: its basic side chains carry positive charges that must be balanced by a negative counterion. Most synthetic peptides are isolated as the trifluoroacetate (TFA) salt, because TFA is used both to cleave the peptide from the resin and as the ion-pairing agent in reversed-phase HPLC purification.^[1] The counterion can be a substantial fraction of the powder’s weight, which is one reason purity and net peptide content differ; some material is converted to the acetate salt instead. The trade-offs between the two are the subject of TFA vs Acetate in Peptides.

Residual solvents, water and metals. Synthesis and purification use solvents that must be driven off during drying, and any that remain are residual solvents, controlled under the general standard ICH Q3C.^[2][15] Freeze-drying leaves a defined amount of residual water, measured by the Karl Fischer method, and because water and counterion both add mass without adding peptide they are quantified so that the true peptide content can be worked out. Trace metals from catalysts and equipment are elemental impurities, controlled under ICH Q3D.^[2][16] None of these show up in the HPLC purity figure; they are reported in their own lines on a certificate of analysis, which is why a complete COA carries far more than a single purity number, as Understanding Peptide COA Testing sets out.

How impurities are separated, weighed and named

Impurities are found by two complementary measurements: a separation that resolves the target from everything near it, and a mass measurement that identifies what each separated species is. Neither alone is enough, because some impurities differ from the target in shape but not in mass, and others in mass but barely in shape.

The workhorse separation is reversed-phase high-performance liquid chromatography (RP-HPLC), which spreads the mixture out in time according to how strongly each molecule sticks to a non-polar column, and reports each species as a percentage of total peak area — the number quoted as “purity.” What that measurement can and cannot show is the subject of What Is HPLC. The companion measurement is mass spectrometry, which weighs each molecule and lets an analyst read a deletion, insertion, oxidation or deamidation straight off the mass difference to the target; the method is described in What Is Mass Spectrometry. The FDA’s synthetic-peptide guidance recommends “sensitive and high resolution analytical procedures (e.g., UHPLC-HRMS)” to detect and characterise peptide-related impurities, and encourages orthogonal methods covering primary sequence, secondary structure and aggregation state.^[2]

The pharmacopoeial name for the peptide-related family is related substances or related peptides, and this is the heading a certificate of analysis groups them under. The hardest impurities to catch, as the aspartimide and epimer cases show, are those that are isobaric with the target and co-elute with it; these are exactly why high-resolution LC-MS and, where needed, chiral or disulfide-mapping methods are used together rather than relying on a single technique.^[1][6]

Reporting, identification and qualification thresholds

Because no peptide is perfectly pure, quality systems do not demand zero impurities; they set percentage thresholds at which an impurity must be reported, structurally identified, and shown to be acceptable. A research powder is not held to the full pharmaceutical system, but the same thresholds explain how the regulated world thinks about the numbers on a COA.

For a peptide handled as a pharmaceutical substance, the 2014 review describes the expectation that peptide-related substances meet a reporting threshold of 0.1 percent, an identification threshold of 0.5 percent and a qualification threshold of 1.0 percent, with the total level of related impurities not exceeding 5 percent.^[1] These are the same tiers used for small-molecule drug substances under ICH Q3A.^[3] The FDA’s 2021 guidance for certain synthetic peptides sets a specific expectation for generic versions: applicants should identify — meaning characterise the structure of — each peptide-related impurity present at 0.10 percent of the drug substance or greater, and any new specified peptide-related impurity should be held to no more than 0.5 percent, a level the agency links to the risk of immunogenicity.^[2]

These figures are drawn from the pharmaceutical framework and apply to approved and generic peptide medicines, not to laboratory research chemicals, which carry no such regulatory requirement. They are included here because they are the clearest published statement of how a peptide-related impurity is judged, and because a research buyer reading a certificate of analysis is looking at the same kind of number. What “research grade” does and does not guarantee is covered in Peptide Purity Grades Explained.

What a purity number does and does not tell you

A purity figure is a single number that stands in for this entire landscape, and understanding its limits is the practical payoff of knowing the impurity classes. Purity by HPLC is the fraction of the peptide material that is the target sequence, measured as peak area; it is not the fraction of the powder that is peptide, and it does not capture impurities that hide under the main peak.

Two gaps follow directly. First, purity and net peptide content are different measurements: a vial can read 98 percent pure by HPLC yet be well under 98 percent peptide by weight once the counterion and bound water are subtracted, because those are not peptides and never appear in the chromatographic peak. Second, HPLC purity systematically under-counts the impurities that are isobaric with and co-elute with the target — the beta-aspartyl peptides, the epimers, the disulfide-scrambled monomers — which is why high-resolution mass spectrometry and, for sensitive sequences, orthogonal methods matter.^[2][6] A high purity number from a method that cannot see a given impurity is not evidence that the impurity is absent. This is the core reason a certificate of analysis should name the method, report identity by mass spectrometry alongside purity by HPLC, and be specific to the lot in the vial — the themes of Understanding Peptide COA Testing.

For reference, Patriot Labs is a first-responder-owned, US-based company, and every batch it sells is tested by an independent US laboratory by HPLC for purity and mass spectrometry for identity, with the certificate of analysis published on the product page — the two measurements this guide describes as the minimum needed to see the impurity picture.

What this guide does not establish

This guide is an educational account of the chemistry of peptide impurities and the analytics used to measure them. Several limits are worth stating plainly.

• It describes classes, not any specific product. Which impurities are present, and at what level, is a property of an individual lot and its certificate of analysis, not something that can be inferred from a compound’s name.
• The thresholds cited are pharmaceutical. The reporting, identification and qualification figures apply to approved and generic peptide medicines under pharmacopoeial and regulatory frameworks; research-grade laboratory chemicals carry no equivalent requirement, and the figures are given only as a reference point.^[1][2][3]
• Mass changes are chemistry, not measurements of a product. Values such as about 16 daltons for an added oxygen or about 1 dalton for deamidation follow from the atoms involved; they describe the reaction, not any particular vial.
• Nothing here concerns use in a person or animal. Immunogenicity is discussed only as the reason regulators set impurity limits for medicines; it is not a statement about any research compound, and this guide does not describe how to use any product.
• Nothing here describes where any peptide is synthesised. The synthesis chemistry is general; it is not a claim about the origin of any specific material.

Frequently asked questions

What are peptide impurities?

Peptide impurities are everything in a vial that is not the intended target peptide. They fall into two groups: peptide-related substances, which are molecules closely related to the target, such as deletion and truncation sequences, insertion sequences, epimers, and oxidation, deamidation, dimer and aggregate products; and non-peptide impurities, which are the counterions, residual solvents, water and inorganic residues left behind by synthesis and purification.

What is a deletion sequence in a peptide?

A deletion sequence is a chain that is missing one or more of the amino acids in the intended sequence, produced when a coupling step does not go to completion and the chain continues to grow without that residue. It is the most common synthesis-related impurity, and it is lighter than the target peptide by the mass of the missing residue, which is how mass spectrometry recognises it.

Why is a research peptide not 100% pure?

Because every step that builds and processes a peptide produces a small amount of something slightly different from the target. Chain assembly misses an occasional coupling, protecting groups do not always come off cleanly, sensitive residues oxidise or rearrange, and purification cannot fully remove by-products that are nearly identical to the target. A purity figure such as 98% states how much of the peptide material is the target sequence; the remainder is made up of these related substances.

What is aspartimide formation?

Aspartimide formation is a side reaction in which an aspartate residue cyclises with the neighbouring backbone nitrogen to form a five-membered ring, which then opens into a mixture of normal and beta-linked peptides and their mirror-image D-epimers. It is most severe when aspartate is followed by glycine, asparagine or arginine, and because several of its products share the target’s mass, they are among the hardest impurities to detect and to remove.

What does the other 2% of a 98% pure peptide contain?

It is the sum of the peptide-related substances that the HPLC method counts: deletion and truncation sequences, insertion sequences, epimers and aspartimide products, and oxidation, deamidation and dimer products, plus any co-eluting material. The purity figure does not include counterions, water or residual solvents, which are measured by separate tests and reported separately on a certificate of analysis.

How are peptide impurities detected?

Mainly by reversed-phase HPLC, which separates the target from related substances and reports each as a percentage of total peak area, and by mass spectrometry, which weighs each species and identifies it from its mass difference to the target. Regulators recommend high-resolution LC-MS, because some impurities, such as epimers and beta-aspartyl peptides, share the target’s mass and need the two methods used together.

What are peptide-related substances?

Peptide-related substances is the pharmacopoeial term for impurities that are themselves peptides closely related to the target molecule, as opposed to non-peptide impurities such as solvents and counterions. It is the category a certificate of analysis groups under headings such as related substances or related peptides.

Is net peptide content the same as purity?

No. Purity, measured by HPLC, is the fraction of the peptide material that is the target sequence. Net peptide content is the fraction of the total powder weight that is peptide at all, as opposed to water, counterions and salts. A vial can be high in one and lower in the other, which is why a certificate of analysis reports both.

References

1. D’Hondt, M., Bracke, N., Taevernier, L., Gevaert, B., Verbeke, F., Wynendaele, E., & De Spiegeleer, B. (2014). Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis, 101, 2–30. doi:10.1016/j.jpba.2014.06.012
2. U.S. Food and Drug Administration (May 2021). ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-certain-highly-purified-synthetic-peptide-drug-products-refer-listed-drugs-rdna-origin
3. International Council for Harmonisation (2006). ICH Q3A(R2): Impurities in New Drug Substances. https://www.ich.org/page/quality-guidelines
4. Merrifield, R. B. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society, 85(14), 2149–2154. doi:10.1021/ja00897a025
5. Mergler, M., Dick, F., Sax, B., Weiler, P., & Vorherr, T. (2003). The aspartimide problem in Fmoc-based SPPS. Part I. Journal of Peptide Science, 9(1), 36–46. doi:10.1002/psc.430
6. Merck / Sigma-Aldrich. Overcoming Aspartimide Formation (technical article on Fmoc-Asp side-chain protection, citing Mergler et al. 2003 and Behrendt et al. 2015–2016). https://www.sigmaaldrich.com/technical-documents/technical-article/chemistry-and-synthesis/peptide-synthesis/overcoming-aspartimide-formation
7. Behrendt, R., Huber, S., Martí, R., & White, P. (2015). New t-butyl based aspartate protecting groups preventing aspartimide formation in Fmoc SPPS. Journal of Peptide Science, 21(8), 680–687. doi:10.1002/psc.2790
8. Sandner, M. (2024). Common Side Reactions in Fmoc Solid-Phase Peptide Synthesis. Iris Biotech GmbH (technical blog). https://iris-biotech.de/en/blog/common-side-reactions-in-fmoc-solid-phase-peptide-synthesis
9. Yang, Y., & Hansen, L. (2022). Optimized Fmoc-Removal Strategy to Suppress the Traceless and Conventional Diketopiperazine Formation in Solid-Phase Peptide Synthesis. ACS Omega, 7(14), 12015–12020. doi:10.1021/acsomega.2c00214
10. Mthembu, S. N., Chakraborty, A., Schönleber, R., Albericio, F., & de la Torre, B. G. (2024). Morpholine, a strong contender for Fmoc removal in solid-phase peptide synthesis. Journal of Peptide Science, 30(2), e3538. doi:10.1002/psc.3538
11. Vilaseca, M., Nicolás, E., Capdevila, F., & Giralt, E. (1998). Reduction of methionine sulfoxide with NH₄I / TFA: compatibility with peptides containing cysteine and aromatic amino acids. Tetrahedron, 54(50), 15273–15286. doi:10.1016/S0040-4020(98)00954-5
12. Stierandová, A., Sepetov, N. F., Nikiforovich, G. V., & Lebl, M. (1994). Sequence-dependent modification of tryptophan by the Pmc protecting group of arginine during TFA deprotection. International Journal of Peptide and Protein Research, 43(1), 31–38. doi:10.1111/j.1399-3011.1994.tb00373.x
13. Yang, Y. (2016). Side Reactions in Peptide Synthesis. Academic Press. ISBN 978-0-12-801009-9.
14. Nicolás, E., Pedroso, E., & Giralt, E. (1989). Formation of aspartimide peptides in Asp-Gly sequences. Tetrahedron Letters, 30(4), 497–500. doi:10.1016/S0040-4039(00)95238-9
15. International Council for Harmonisation. ICH Q3C(R8): Impurities — Guideline for Residual Solvents. https://www.ich.org/page/quality-guidelines
16. International Council for Harmonisation. ICH Q3D(R2): Guideline for Elemental Impurities. https://www.ich.org/page/quality-guidelines

For the numbers these impurities add up to, see Peptide Purity Grades Explained and What Is Net Peptide Content; for the measurements that find them, see What Is HPLC and What Is Mass Spectrometry; and for how a certificate of analysis ties it together, see Understanding Peptide COA Testing.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes the chemistry and analysis of peptide impurities in general terms; it is not medical advice, does not describe how to use any product, and makes no claim about the purity, impurity profile or manufacturing location of any specific product.